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in patients with ankylosing spondylitis than in
matched population controls and is associated
with impaired spinal mobility: a comparative
study
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Abstract
Introduction: Pulmonary involvement is a known manifestation in patients with ankylosing spondylitis (AS).
However, previous studies have been based on small samples and the reported prevalence and associations with
typical clinical features vary. The purpose of this study was to compare pulmonary function (PF) in patients with AS
and population controls, and to study associations between PF and disease related variables, cardio-respiratory
fitness and demographic variables in patients with AS.
Methods: In a cross-sectional controlled study, 147 AS patients and 121 controls underwent examinations,
including demographic variables, laboratory (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)) and
clinical measures (disease activity (AS disease activity score, ASDAS), physical function (Bath ankylosing spondylitis
functional index, BASFI), spinal mobility (Bath ankylosing spondylitis metrology index, BASMI), chest expansion,
cardio-respiratory fitness (peak oxygen uptake, VO2peak) and pulmonary function test (PFT) (spirometry)).
Cumulative probability plots were used to visualize associations between the ASDAS and BASMI scores and the
corresponding forced vital capacity (FVC%, percentage of predicted value controlled for the influence of
confounding factors) score for each patient. Univariate ANCOVAs were performed to explore group differences in
PF adjusting for relevant variables, and a multiple regression model was used to estimate the explanatory power of
independent variables (demographic, disease related, VO2peak) on restrictive ventilatory impairment (FVC%).
Results: AS patients showed significantly lower PF values compared with controls, and significantly more patients
were categorized with restrictive pattern (18% vs. 0%, P < 0.001). Cumulative probability plots showed significant
associations between spinal mobility measures (BASMI) and FVC% for individual patients. BASMI, chest expansion
and male gender contributed significantly and independently in a multiple regression model predicting the
variation of FVC% in AS patients, whereas disease activity, physical function and VO2peak did not contribute
significantly. The final model explained 45% of the variance in FVC% (P < 0.001).
Conclusions: This study showed significantly impaired pulmonary function in the AS patients compared to
controls and reference data, and demonstrated a clear relationship between reduced spinal mobility and restrictive
PF in AS patients. The results support the assumption of an association between musculoskeletal limitations and
restrictive respiratory impairment in AS, emphasizing the importance of maintaining spinal flexibility in the
management of the disease. Further, patients with severely reduced spinal mobility should be referred for
pulmonary function examination and relevant follow-up treatment.
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Introduction
Ankylosing spondylitis is a chronic, systemic, inflamma-
tory, rheumatic disease affecting mainly the axial skeleton
and sacroiliac joints, causing characteristic inflammatory
back pain and resulting in varying degree of structural and
functional impairments [1]. AS may also be associated
with extra-spinal manifestations, involving peripheral
joints, eye, skin, bowel and an increased risk of cardiovas-
cular morbidity [2]. Additionally, pulmonary involvement
is a known manifestation, emerging either as interstitial
lung disease or as a consequence of chest wall abnormal-
ities [3,4]. Both of these conditions may lead to restrictive
pulmonary function, typically presented as restrictive pat-
tern in a pulmonary function test (spirometry).
AS is characterized by inflammation in the thoracic
vertebrae and in the costovertebral joints, causing gra-
dual fusion and ossification of the joints, for some
patients ultimately resulting in increased dorsal kypho-
sis, rigidity of the thorax and permanent chest wall
immobility [5,6]. Reduced lung volumes have been sug-
gested to be a consequence of mechanical limitations,
due to bony ankylosis of the thoracic joints [7], because
restrictive respiratory impairment frequently has been
reported to be associated with low thoracic expansibility
[6-10]. Additionally, some claim that ongoing inflamma-
tory processes in the thoracic joints may explain limita-
tions of chest excursions, by causing pain and stiffness,
and thus contributing to reduced pulmonary function
[5,9,11]. Others suggest that pleuropulmonary tissue is
an independent primary target in AS [12,13], and that
inflammatory processes in the lung parenchyma with a
tendency to fibrosis might be as significant as mechani-
cal factors in the development of reduced pulmonary
function in AS [9,14,15]. However, reports have differed
regarding whether pulmonary function worsens with
disease progression [5], and whether respiratory restric-
tion correlates with limitation of chest wall movements
[5,6,13,16,17].
Further, the frequency of pulmonary involvement var-
ies depending on the diagnostic method applied, and
has been reported to be between 20 and 57% using
spirometry [4,8,12,18], between 1 and 15% with radio-
graphic evaluation, and between 40 and 80% in studies
in which high resolution computed tomography was
applied [4,9,13,14,19-21].
Previous studies on this field have been based on
small study samples. Hence, the associations between
anthropometric, musculoskeletal and disease related fac-
tors and pulmonary function abnormalities in AS
patients need to be more thoroughly explored.
The aims of this study were to characterize pulmonary
function variables in patients with AS, and to examine
whether, and in what respect, these variables differ from
those observed in population controls. Also we aimed to
investigate possible associations between pulmonary
function and demographic, disease specific and labora-
tory measures and cardio-respiratory fitness.
This article provides findings from a comprehensive
clinical assessment of patients with AS, and the results
are compared to population controls.
Materials and methods
Study design and selection of patients and population
controls
In a cross-sectional study, patients clinically diagnosed
with AS by a rheumatologist and aged between 18 and
70 years were recruited from a hospital-based register.
Additionally, 121 population controls were randomly
selected from the national register by Statistics Norway
to match age, gender and residential area of the AS
patients. The only exclusion criterion was a history of
inflammatory arthritis.
Ethics
All participants gave their written consent before inclu-
sion, and the procedures followed The World Medical
Association Declaration of Helsinki. The protocol was
reviewed and approved by The National Committee for
Medical Research Ethics, Southern Norway (S-02059
and S-03066), and the Norwegian Data Inspectorate
provided licence to store and register individual health
information (08/00165-2/sve).
Clinical assessments and self-reported data
Demographic variables (age, disease duration, education
level, smoking history, work and marital status) were
recorded for all participants using a questionnaire. Dis-
ease activity was measured by inflammatory markers (C-
reactive protein (mg/l), CRP), erythrocyte sedimentation
rate (mm/h), ESR) and by the AS Disease Activity Score
(ASDAS) [22]. The ASDAS includes CRP-levels (mg/l)
in addition to patient assessment of peripheral joint
pain/swelling, total back pain, duration of morning stiff-
ness (Bath Ankylosing Spondylitis Disease Activity
Index, BASDAI, Q1, Q2 and Q6 [23]) and patient global
assessment of disease activity (0 to 10). The scores were
categorized according to published cut-offs with low
ASDAS defined as < 1.3, moderate ASDAS < 2.1, high
ASDAS ≤ 3.5 and very high ASDAS > 3.5 [24]. The
ASDAS can be used to discriminate between groups of
patients, and it provides information about the actual
disease activity state that has been reached [22].
Patient-reported physical function was measured with
the Bath Ankylosing Spondylitis Functional Index
(BASFI). BASFI consists of eight questions relating to
specific functions on activity level and two questions
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reflecting the person’s ability to cope with everyday life.
The responses were given on NRS. The mean score of
10 items gave the final BASFI score ranging from 0
(easy) to 10 (impossible) [25].
Anthropometric measures were examined by the Bath
Ankylosing Spondylitis Metrology Index (BASMI) [26],
by chest expansion and by body mass index (BMI).
BASMI includes five clinical examinations of the spinal
column and the hip joints; that is the distance from tra-
gus to wall (TWD), lumbar flexion (l-Schober), lateral
lumbar flexion, cervical rotation and inter-malleolar dis-
tance. Each of the five measurements was classified into
11 equal sections, and the mean of the five scores pro-
duced a BASMI score from 0 to 10; low score indicating
normal function. BASMI is suitable for assessing spinal
mobility across the whole range of disease severity [27].
The test is comprehensive, quick, reproducible and sen-
sitive to change across the disease spectrum [26], and is
shown to be valid, reliable and responsive [28,29]. Chest
expansion was measured with tape measure placed cir-
cumferentially around the chest on level with the
xiphoid process. The difference (cm) in circumference
of the chest between maximum inspiration and maxi-
mum expiration was recorded (best of two attempts,
rounded at 0.1 cm) [30]. Measurements of the weight
and height were recorded and the BMI was calculated
by the formula weight (kg)/height2 (cm) [31].
Cardio-respiratory fitness was evaluated by a maximal
walking test for estimation of peak oxygen uptake
(VO2peak), according to the Balke modified protocol
[32], using a multistage treadmill test of graded exercise.
The estimated peak oxygen uptake (VO2peak) was com-
puted from The American College of Sports Medicine
(ACSM) formulas for graded walking (speeds ≤ 8 km/h,
VO2 ml·kg
-1·min-1 = (0.1·ms-1 + 1.8·ms-1·inclination (%)
+ 3.5) or running (speeds > 8 km/h, VO2 ml·kg
-1·min-1
= (0.2·ms-1 + 0.9·ms-1·inclination (%) + 3.5) [33].
Pulmonary function test
All participants underwent a pulmonary function test
(PFT), evaluated by means of a spirometer (Spida 5,
USB Spirometry from Micro Medical Ltd, Rochester,
Kent, UK, 2006). The spirometric measurements were
performed with the subject sitting upright with a nose
clip attached. Spirometric testing was done by a
trained physiotherapist in accordance with guidelines
set by the American Thoracic Society and the Eur-
opean Respiratory Society (ATS/ERS) [34] and
included measurements of:
FVC-Forced Vital Capacity: the maximal volume of air
delivered during an expiration made as forcefully and
completely as possible starting from full inspiration; that
is, vital capacity performed with a maximally forced
expiratory effort, expressed in liters.
FEV1 - Forced Expiratory Volume in one second: the
volume, expressed in liters, delivered in the first second
of the FVC manoeuvre.
PEF-Peak Expiratory Flow: the maximum expiratory
flow achieved from a maximum forced expiration, start-
ing without hesitation from the point of maximal lung
inflation, expressed in liter/minute.
FEV1/FVC%-the absolute ratio; derived from observed
values (not percent predicted) (liters/liters × 100). Pri-
marily used in the diagnostics of obstructive ventilatory
disease [35].
Additionally, observed values were expressed as per-
centage of predicted values to control for the influence
of age, gender, weight and height. The published
equations of the European Community for Coal and
Steel (ECCS) [36] were internalized in the spirometry
equipment and used as reference data. Additionally, data
from the matched population controls served as refer-
ences and basis for comparisons. Repeated measure-
ments were performed until three acceptable
manoeuvers were obtained, and the largest FVC and
FEV1 values were recorded for further analysis. Based
on these results, the patients were categorized as having
a restrictive ventilatory pattern (FVC ≤ 80%, FEV1/FVC
≥ 70%, decreased or normal FEV1), obstructive ventila-
tory pattern (FEV1/FVC < 70%, decreased FEV1, normal
or decreased FVC) or normal pulmonary function (FVC
> 80%, FEV1 > 80%, FEV1/FVC > 80%) [37-39].
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware (Statistical packages for the social sciences) for
Windows, version 17.0 (SPSS Norway, Oslo, Norway).
The Independent sample t test was used for intergroup
comparisons of continuous, normally distributed data
and the Mann Whitney U test for comparisons of
skewed distributions. Results are presented as mean
(SD) or median (min-max) values. Intergroup compari-
sons of categorical data were analyzed using the Chi
Square test. Results are presented as summaries of
observed frequencies (counts) together with rounded
percentages.
The associations among spinal mobility (BASMI) and
disease activity (ASDAS) and pulmonary function (FVC
%) are visualized with combined scatter and cumulative
probability plots. These plots combine the FVC% score
with the corresponding mobility (BASMI) and disease
activity (ASDAS) score for each individual. The BASMI
and ASDAS scores were plotted in cumulative order
(from lowest value to highest). The combined procedure
yielded a scatter plot (observation of two variables com-
bined), in which one of the variables were plotted
against its cumulative probability. Univariate ANCOVA
analyses were performed to explore differences in
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pulmonary function between patients and controls
adjusting for age, gender, height and smoking status.
Further, a multiple linear model was used to estimate
the explanatory power of independent variables (demo-
graphic, disease related, VO2peak) on restrictive pulmon-
ary impairment (FVC%) [40,41]. A P-value of 0.05 was
considered statistically significant.
Results
Participants
Two hundred and fifty patients with AS were invited,
and 162 (59%) gave their informed consent to partici-
pate. Fifteen did not complete the pulmonary assess-
ments, thus, a total of 147 (91%) of the 162 patients
with informed consent were included in the analyses.
Three hundred and twenty-nine letters were sent to
invite potential controls and 139 (42%) accepted partici-
pation. Of these, a total of 121 of the 139 (87%) controls
who accepted participation completed the pulmonary
function tests and were included in the analyses.
For both the AS patients and the population controls,
the participating subjects were older (P = 0.04 and P =
0.03, respectively) and a higher proportion were living in
the western part of Oslo (P = 0.01, P = 0.06, respec-
tively) compared with the subjects who rejected partici-
pation. There were no significant differences in gender
between participating and non-participating subjects
among AS patients and population controls.
Demographic and disease related variables
Demographic variables of the AS patients and the popu-
lation controls are shown in Table 1. Patients were
younger (P = 0.01), more educated (P = 0.03) and a
higher proportion were reported to receive social secur-
ity benefits (P < 0.001) compared with controls. The
other demographic parameters showed no significant
differences between the groups.
The inflammatory marker values were significantly
higher in patients than population controls (CRP, P <
0.001, ESR, P < 0.001). Furthermore, the population
controls had significantly better aerobic capacity
(VO2peak, P = 0.002), better self-reported physical func-
tion (BASFI, P < 0.001) and less restricted spinal mobi-
lity (BASMI, P < 0.001). Half of the AS patient group
had high or very high disease activity (ASDAS ≥ 2.1)
(Table 1).
Pulmonary function in patients and controls
The PFT showed significantly lower values for AS
patients compared to controls with regard to FVC% (97
vs 105, P < 0.001), FEV1% (90 vs 99, P < 0.001) and PEF
% (95 vs 99, P = 0.05). Most of the AS patients were
categorized with normal pulmonary function, but 18%
(n = 27) were categorized with restrictive pattern. As
none of the population controls showed a restrictive pat-
tern, the proportion of pulmonary impairment in the two
groups was significantly different (P < 0.001) (Table 2).
Approximately 10% of the AS patients and 9% of the con-
trols were categorized with obstructive pattern.
Among the 27 AS patients with a restrictive pattern, 21
(78%) were males, median age was 57 years (range 33,
68), median disease duration was 27 years (range 18, 46),
9 (33% were using biological anti-tumor necrosis factor
therapy and 15 (56%) were lifelong non-smokers. Patients
with restrictive pattern were significantly older (P =
0.015) and had longer disease duration (P = 0.054) than
patients with normal pulmonary function (Table 3).
Furthermore, patients with restrictive pattern had signifi-
cantly reduced spinal mobility (BASMI, (P < 0.001), chest
expansion (P < 0.001), lumbar flexion (P < 0.001) and
Table 1 Characteristics of AS patients and population
controls
Characteristics AS Patients
(n = 147)
Controls
(n = 121)
P
-value
Age (yr) median (range) 48.5 (30 to
70)
56.0 (30 to
70)
0.01a
Male n (%) 93 (63.3) 68 (56.2) 0.24d
Height (cm), mean (SD) 174.1 (9.7) 173.4 (8.9) 0.54b
Weight (kg) mean (SD) 77.4 (13.7) 77.5 (13.7) 0.98b
BMI (kg/cm2) mean (SD) 25.5 (3.5) 25.7 (3.7) 0.59b
ASDAS n (%) -
< 1.3 (low) 23 (15.6)
1.3 to 2.1 (moderate) 45 (30.6)
2.1 to 3.5 (high) 58 (39.5)
> 3.5 (very high) 10 (10.9)
BASFI 2.1 (0 to 10) 0.3 (0 to 6.3) <
0.001a
BASMI 3.3 (1.8) 1.7 (0.9) <
0.001b
CRP 3.0 (1.57) 1.0 (1.103) <
0.001a
ESR 16.5 (1.90) 8.0 (1.70) <
0.001a
VO2peak (ml/kg/min) 39.4 (8.0) 40.4 (7.5) 0.002
e
Smoking
Lifelong non-smoker, n
(%)
74 (50.0) 59 (48.8) 0.81c
Ex-smoker, n (%) 48 (32.4) 38.2 (30.6)
Current smoker, n (%) 26 (17.6) 22.9 (20.7)
> 12 yr education, n (%) 103 (71) 68 (57) 0.03d
Currently employed, n (%) 111 (76.6) 99 (83.2) 0.18d
Social security benefit, n (%) 57 (39.4) 15 (12.6) <
0.001d
Married/living with partner, n
(%)
99 (67) 71 (60) 0.20d
Anti-TNF-alpha medication 32 (22) -
a Mann Whitney U test, bIndependent Sample t-test, cChi Square test, d Chi
Square test with correction for continuity (2 × 2 table), eANCOVA adjusted for
age and education.
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lateral lumbar flexion (P < 0.001) compared to patients
with normal pulmonary function. The occurrence of
increased dorsal kyphosis (measured as TWD) was signif-
icantly higher in patients with restrictive ventilatory pat-
tern with a median of 18.5 cm (range 11, 38) compared
to patients with normal pulmonary function median 12
cm (range 8, 44, P < 0.001). Additionally, physical func-
tion (BASFI, P = 0.003) and cardio-respiratory fitness
(VO2peak, P = 0.002) were significantly reduced in
patients with restrictive respiratory impairment.
Smoking
When comparing AS patients who never smoked (n =
74) with ex-smokers/current smokers (n = 73), we
found statistically significant differences (ex-smokers/
smokers worse health) in all measures of disease activity
(ASDAS, BASDAI, ESR, CRP) (Table 4). Additionally,
chest expansion and VO2peak were significantly poorer
in the group of smokers and ex-smokers. However,
there were no significant differences in pulmonary func-
tion, self-reported pulmonary disease or physical func-
tion between AS patients who never smoked and ex-
smokers/current smokers. The group of smokers/ex-
smokers was less frequently on biologic treatment (P >
0.007).
Associations between pulmonary function and relevant
variables
Figure 1 presents scatter plots of the spinal mobility
scores (BASMI) and the disease activity scores (ASDAS)
in cumulative order versus the FVC% score. The infor-
mation obtained from these plots can be exemplified by
the association between BASMI and FVC% (Figure 1A):
The probability plot of the BASMI scores visualizes that
approximately 20% of the patients had a BASMI score
of 4.5 or more. Almost all these patients had a FVC%
score less than 80 (indicating restrictive respiratory
impairment), whereas for disease activity (ASDAS), this
association is lacking (Figure 1B).
A multiple regression model was built to assess how
demographic and clinical variables and aerobic capacity
could predict the variation in FVC% in the patient
group. Male gender, BASMI and chest expansion con-
tributed independently and significantly, and the final
model explained 45% of the variance in FVC% (P <
0.001) (Table 5).
Discussion
This study showed significantly impaired pulmonary
function in the AS patients compared to reference data
and to the population controls. Furthermore, significant
associations were found between pulmonary function
and the typical clinical features of AS: reduced spinal-
and chest-wall mobility.
The results of this study are in agreement with pre-
vious studies, although a lower prevalence of restrictive
abnormalities was observed. We found a prevalence of
18% of restrictive disorders, compared to the reported
prevalence between 20 and 57% in other studies
[4,8,12,14,15,18,20,21,42,43]. However, these studies
were based on small sample sizes, ranging from 17 to 55
subjects, potentially influencing the representativeness.
Hence, the results of this study indicate that restrictive
pulmonary function may be a consequence of AS, but
the prevalence of restrictive involvement may be lower
than previously reported.
Another possible explanation of the lower prevalence
of restrictive impairment found in this study may be
attributed to the assessment of pulmonary function.
Lung volumes are related to body size, and standing
height is the most important correlating variable [39].
However, patients with AS often loose height due to
increasing dorsal kyphosis as the disease progresses.
Some of the previous studies have used patient’s original
Table 2 Measures of pulmonary function in AS patients and controls
PFT AS patients (n = 147) Controls (n = 121) ß (95% CI) P-value
FVC (liters) mean (SD) 4.0 (1.2) 4.1 (1.0) 0.3 (0.14,0.45) < 0.001a
FVC% 97.2 (18.1) 104.9 (15.2) < 0.001b
FEV1 (liters) mean (SD) 3.1 (0.9) 3.2 (0.9) 0.3 (0.18,0.43) < 0.001
a
FEV1% 89.8 (16.0) 98.5 (14.5) < 0.001
b
PEF (liters/minute) mean (SD 464.7 (121.4) 469.1 (120.1) 20.5 (1,41.1) 0.05a
PEF% 95.2 (17.6) 99.4 (16.6) 0.05b
FEV1/FVC% 76.5 (7.5) 77 (6.4) 0.38
b
Respiratory pattern
Normal n (%) 105 (71.4) 110 (90.9) < 0.001c
Restrictive pattern n (%) 27 (18.4) 0 < 0.001c
Obstructive pattern n (%) 15 (10.2) 11 (9.1) 0.76c
FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PEF, peak expiratory flow; FVC%, FEV1%, PEF%, predicted percentages adjusted for age,
gender, smoking and height (adjustments made in the device); FEV1/FVC%, absolute ratio (derived from observed values). A, linear regression, adjusted for age,
gender, smoking and height; b, t-test; c, chi-square test
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height or height from arm span measurement to calcu-
late predicted normal values [6,44]. Yet, since the relia-
bility of recalled height may be questionable [39], the
actual height measured at time of testing was used in
this study. Hence, for patients who have lost height, the
comparisons of PFT results were done with reference
values appropriate for originally shorter persons. As a
consequence, we may have failed to discover some cases
of restrictive pulmonary impairment and, consequently,
underestimated the prevalence.
Furthermore, the population in this study was well
educated, married or living with a partner, primarily of
Norwegian ethnicity and recruited from a non-industrial
(sub-) urban district area with high socio-economic sta-
tus (SES). Within the city of Oslo, differences in health,
exercise habits and mortality rates between districts are
significant, and strongly related to SES [45]. Adverse
effects of low SES on pulmonary function are well docu-
mented, as low SES often is associated with unfavorable
environmental conditions, such as increased exposure to
indoor and outdoor pollution, increased occupational
exposures and decreased access to health care. More-
over, genetic factors influencing lung function may be
attributable to differences in SES [37]. The high SES
values in this sample may be associated with the low
prevalence of pulmonary impairment.
Table 3 AS patients with normal pulmonary function
versus patients with restrictive pattern
Normal pulmonary
function (n = 105)
Restrictive
pattern (n = 27)
P-
value
Age (yr), median
(min, max)
46 (30,70) 57 (33,68) 0.015
Males, n (%) 66 (63) 21 (78) 0.218
Disease duration
(yr)
22 (7,55) 27 (8,46) 0.054
Lifelong non-
smokers, n (%)
53 (51) 15 (56) 0.799
FVC (liters), mean
(SD)
4.3 (1.1) 2.8 (0.7) <
0.001
FVC % 103.4 (12.8) 69.4 (6.6) <
0.001
FEV1 (liters) 3.4 (0.9) 2.2 (0.5) <
0.001
FEV1 % 96.6 (12.2) 68.6 (7.9) <
0.001
PEF (liters/
minute)
493.2 (119.9) 400.0 (101.3) <
0.001
PEF % 100.0 (16.0) 85.5 (15.8) <
0.001
FEV1/FVC % 77.4 (6.1) 79.4 (8.3) 0.158
ASDAS 2.8 (1.0) 3.1 (0.9) 0.140
BASDAI 4.1 (2.1) 4.3 (2.0) 0.709
BASFI 1.8 (0.8, 8.0) 2.9 (0.9, 10.0) 0.003
BASMI 2.9 (1.6) 5.4 (1.8) <
0.001
Chest expansion
(cm)
4.6 (2.1) 2.9 (1.8) <
0.001
Lumbar flexion
(cm)
4.3 (1.4) 2.4 (1.6) <
0.001
Lumbar lateral
flexion (cm)
14.4 (5.6) 7.6 (5.5) <
0.001
TWD (cm) 11.8 (7.8, 43.5) 18.5 (10.5, 38.0) <
0.001
CRP 3.0 (1.0, 57.0) 7.0 (1.0, 28.0) 0.063
ESR 15.0 (2.0, 83.0) 28.0 (1.0, 90.0) 0.006
VO2peak 41.0 (7.2) 35.9 (8.9) 0.002
Anti-TNF-a-
medication, n (%)
21 (20) 9 (33) 0.201
PFT results, clinical and laboratory measures in the AS patients (n = 132).
Mann Whitney U test for comparisons of skewed distributions, Independent
Sample T-test for normally distributed data. FEV1%, FVC% and PEF% are
adjusted for age, gender and actual height. FEV1/FVC % = absolute FEV1/FVC
ratio. The other measurements are not adjusted. Chi-Square test for
comparisons of categorical data
Table 4 Comparisons of PF and clinical variables with
regard to smoking habits in AS patients
Test Lifelong non-
smokers(n =
74)
Ex-smokers +
current smokers (n
= 73)
P-
value
Agea (yr) 47.8 (11.8) 51.1 (10.1) 0.07c
Disease durationb (yr) 21.5 (7 to 55) 23 (8 to 47) 0.64d
Self reported
pulmonary disease
(yes/no) n (%)
6 (8.1) 10 (13.9) 0.53e
FEV1 (liters)
a 3.2 (1.0) 3.0 (0.9) 0.18c
FEV1 %
a 89.9 (15.7) 89.6 (16.5) 0.90c
FVC (liters)a 4.1 (1.2) 3.9 (1.1) 0.45c
FVC %a 95.7 (17.4) 98.6 (18.8) 0.33c
PEF (liters/minute)a 469.3 (128.5) 458.8 (114.7) 0.60c
PEF %a 93.6 (18.0) 96.7 (17.1) 0.28c
FEV1/FVC %
a 77.5 (7.4) 75.4 (7.6) 0.09c
ASDAS 2.6 (1.0) 3.0 (0.9) 0.004c
BASDAIa 3.8 (2.0) 4.5 (2.0) 0.040c
ESRb 12 (1 to 90) 19 (2 to 67) 0.047d
CRPb 3 (1 to 57) 5 (1 to 52) 0.018d
BASFIb 1.8 (0 to 10) 2.3 (0 to 8.5) 0.66d
BASMIa 3.3 (1.8) 3.2 (1.8) 0.74
Chest expansion (cm)a 4.8 (2.3) 3.9 (2.0) 0.019c
Lumbar flexion (l-
Schober)a
4.0 (1.7) 4.0 (1.7) 0.90c
Lumbar lateral flexiona 12.9 (6.0) 13.6 (6.3) 0.53c
Tragus to wall
distanceb
13.1 (7.8 to
38.0)
12.0 (8.0 to 43.5) 0.33d
VO2maxa 40.9 (8.4) 38.0 (7.4) 0.037c
Anti-TNF-a-med, n (%) 23 (31) 9 (13) 0.007
Respiratory pattern
Normal (n) (%) 53 (71.6) 52 (71.2) 1.00e
Restrictive pattern (n)
(%)
15 (20.3) 12 (16.4) 0.67e
Obstructive pattern (n)
(%)
6 (8.1) 9 (12.3) 0.43e
a Mean (SD). b Median (min-max). c Independent Sample T test. d Mann
Whitney U test. e Chi Square test
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Reduced spinal mobility and chest expansion and male
gender made the largest contributions to explaining the
variance of pulmonary function in the patient group.
This result is in accordance with several previous stu-
dies, reporting that the restrictive pulmonary disorder
seen in AS patients is associated with increased stiffness
and ankylosis of the spine and costovertebral joints
[9,10,46]. However, neither measures of acute inflamma-
tion, disease activity, smoking, physical function nor car-
dio-respiratory fitness contributed to explaining
pulmonary function in this study. The results indicate
that inflammatory activity is of less importance with
regard to restrictive pulmonary function in this patient
group, but a causal inference cannot be drawn due to
the cross sectional design. The findings do, however,
support the assumption of an association between
musculoskeletal limitations and restrictive pulmonary
impairment, underlining the importance of maintained
spinal flexibility in the management of AS.
Earlier reports have differed concerning whether dis-
ease duration is associated with restrictive pulmonary
impairment in AS or not. This is interesting, because
AS is a chronic, progressive disease. If pulmonary
restrictivity is related to musculoskeletal limitations pro-
gressing with time, a logical consequence would be a
parallel deterioration in pulmonary parameters. In this
study, patients with restrictive pattern were, in agree-
ment with these expectations, significantly older and
had longer disease duration than patients with normal
pulmonary function.
Smoking is recognized as having a negative impact
on patients with respiratory restrictions, independent
A: Cumulative probability plot of BASMI in AS patients B: Cumulative probability plot of ASDAS in AS patients
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Figure 1 Cumulative probability plots of spinal mobility (BASMI) and disease activity (ASDAS) versus FVC%. The probability plot of the
BASMI scores (squared symbols) visualizes that patients with high BASMI scores (the curve bends steeply at approximately 20%) almost always
had low FVC%, while most of the patients with low BASMI scores also had normal FVC%. The B plot shows that among the patients with very
high ASDAS scores (approximately 15%), most had normal FVC%.
Table 5 A multiple linear regression model for 147 AS patients, dependent variable FVC%
Crude Estimates ßa (95% CIb) P-value Adjusted estimatesc ß (95% CI) P-value Final model (R2)
Age -0.3 (-0.6, -0.05) 0.02 ns 0.45
Gender P < 0.001
Female Reference < 0.01 -8.2 (-12.9, -3.5) 0.001
Male -8.3 (-14.2, -2.3)
Smokingd
Lifelong non-smokers, Reference 0.33 ns
Ex-smokers and smokers 2.9 (-3.0, 8.8)
Educationb
≤ 12 years Reference 0.94 ns
> 12 years 0.3 (-6.3, 6.8)
ASDAS -1.4 (-4.5, 1.7) 0.36 ns
BASFI (0 to 10) -1.9 (-3.3, -0.5) < 0.01 ns
BASMI (0 to 10) -5.6 (-6.9, -4.3) < 0.001 -4.1 (-5.4, -2.7) < 0.001
Chest expansion (cm) 4.0 (2.8, 5.1) < 0.001 2.7 (1.6, 3.9) < 0.001
VO2peak 0.6 (0.2, 0.9) < 0.001 ns
a Estimated regression coefficients, b confidence interval, c Adjusted for the other variables in the table, d Smoking (lifelong non-smokers vs ex-smokers and
smokers). e Education (≤ 12 years or > 12 years), ns: not significant in the adjusted model
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of the etiology of the restriction [20]. Yet, in this study,
when comparing lifelong non-smokers (n = 74) with
ex-smokers and current smokers (n = 73), we found
no significant differences in pulmonary function, self-
reported pulmonary disease or physical function
between the AS patients. This result is in agreement
with previous reports [6,7,13]. Surprisingly, we found
significant differences between these two groups con-
cerning all measures of acute inflammation and disease
activity, indicating that smoking is connected to the
general inflammatory process in AS. Earlier reports on
pulmonary function in AS found no differences in dis-
ease activity between smokers and non-smokers [4,20].
However, there are previous descriptions of an associa-
tion between smoking and a more rapid disease pro-
gression and a poorer long-term outcome of AS
[47,48]. The findings of the present study indicate that
smoking is connected to measures of disease activity,
chest expansability and cardio-respiratory fitness, but
probably not directly to measures of pulmonary func-
tion in AS. Furthermore, similar observations were
recently made in an early axial spondyloarthritis
cohort: Patients who smoked were more likely than
non-smokers with the disease to have higher disease
activity, poorer functional status, increased axial
inflammation and increased axial structural damage on
MRI [49]. Moreover, according to the results of the
current study, it seems that smokers are less frequently
treated with biological agents.
The gold-standard definition of restrictive pulmonary
disease requires measurement of total lung capacity
(TLC). Spirometry is very effective at excluding a
restrictive defect, but a classic restrictive pattern on
spirometry does not accurately predict a true restrictive
defect because it represents a true restriction in less
than 60% of cases (38). Thus, measurement of lung
volumes (TLC) is necessary to confirm a restrictive
impairment (39). As data from TLC measurements were
not available in this study, the true prevalence of restric-
tive impairment may be even smaller than reported, and
lung volume data would have provided a more precise
estimate.
We did not produce a category for mixed ventilatory
abnormalities in this study. A mixed defect is charac-
terized by the co-existence of obstruction and restric-
tion (39), defined by reduced TLC and reduced FEV1/
FVC ratio. There were four cases of possible mixed
abnormalities among the AS patients in the present
sample; all had FVC scores well below 80% of pre-
dicted (indicating restriction) combined with a FEV1/
FVC ratio just below 0.7 (indicating obstruction).
Because FVC may be equally reduced in both obstruc-
tion and restriction, we evaluated the individual flow-
volume-curves (which appear differently for restrictive
and obstructive defects [39]) before categorization, and
we let the FVC% score overrule the ratio. All four
cases of doubt were categorized with restrictive venti-
latory pattern.
Another weakness of this study is the lack of data on
radiological changes in skeletal structures. Previous
reports have recognized relationships between radio-
graphic manifestations and BASMI (especially lumbar
flexion and lumbar lateral flexion), but yet, spinal mobi-
lity measures cannot stand proxy for radiographic eva-
luation in an individual patient [50]. An additional
weakness is the lack of CT imaging, as interstitial lung
disease is diagnosed by CT. However, there is little evi-
dence of correlation between lung findings by imaging
and abnormalities measured by spirometry
[11,12,14,16,21]. This study is, however, strengthened by
the relatively large number of subjects included, provid-
ing an opportunity to produce more accurate estimates
and, hopefully, a more representative sample. Further-
more, the comparisons with controls randomly drawn
from the general population and a comprehensive clini-
cal examination may also strengthen the results.
Conclusion
This study showed that patients with AS were more
likely to have restrictive respiratory impairment com-
pared to controls and reference data. However, the pre-
valence of respiratory impairment in this study was
lower than previously reported. The reduced pulmonary
function was closely related to reduced spinal- and chest
wall mobility, whereas measures of disease activity, phy-
sical function, smoking and cardio-respiratory fitness
did not contribute significantly in explaining pulmonary
function. The results emphasize the importance of
maintaining spinal flexibility in the management of AS.
However, the effects of mobility and aerobic exercise on
pulmonary function in AS patients remain to be
explored. The study exposed a need for further exami-
nation of the relationships between the disease specific
changes and pulmonary function in AS. Furthermore,
patients with severely reduced spinal mobility should be
referred to pulmonary function examination and rele-
vant follow-up treatment.
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